Information Provided By: 
Fly News Breaks for November 6, 2015
ENDP
Nov 6, 2015 | 08:43 EDT
Citi analyst Liav Abraham views the post-earnings selloff in shares of Endo as overdone. The pullback is "somewhat inexplicable" and inconsistent with the company's Q3 earnings, Abraham tells investors in a research note. He views current levels as an attractive entry point but admits the stock may be range-bound over the near term as volatility in the specialty pharma space continues. He keeps a Buy rating on Endo with a $72 price target.
News For ENDP From the Last 2 Days
There are no results for your query ENDP
